Total mortalitya · people with antiphospholipid syndrome and a history of stroke or thromboembolic events
It is very uncertain whether standard‐dose VKA plus single antiplatelet agent changes all‐cause mortalitya compared with standard‐dose VKA (very low certainty).
1 finding from 1 review
Mortality ‐ early and intermediate · people requiring treatment for acute DVT
1 finding from 1 review
Stroke‐related mortality · asymptomatic carotid stenosis
Antiplatelet agent showed no clear difference in stroke‐related mortality (CT scan or MRI) compared with placebo (low certainty).
1 finding from 1 review
Mortality ‐ early and intermediate · people requiring treatment for chronic DVT
1 finding from 1 review
Mortality ‐ intermediate and long term · people requiring treatment for chronic DVT
Chronic DVT ‐ antiplatelet agents plus BMP showed no clear difference in mortality ‐ intermediate and long term compared with BMP plus placebo (moderate certainty).
1 finding from 1 review
All‐cause mortality · people with antiphospholipid antibodies and no history of thrombosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · people with antiphospholipid antibodies and no history of thrombosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · people with antiphospholipid antibodies and no history of thrombosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · people with antiphospholipid antibodies and no history of thrombosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
1 finding from 1 review
Total mortality · adults with hypertension (patients with atrial fibrillation, congestive heart failure, pre‐eclampsia or pulmonary hypertension were…
Aspirin showed no clear difference in total mortality compared with placebo (low certainty).
1 finding from 1 review
Total mortalitya · people with antiphospholipid syndrome and a history of stroke or thromboembolic events
High‐dose VKA showed no clear difference in all‐cause mortalitya compared with standard‐dose VKA (low certainty).
1 finding from 1 review
Total mortalitya · people with antiphospholipid syndrome and a history of stroke or thromboembolic events
NOAC (rivaroxaban) showed no clear difference in all‐cause mortalitya compared with standard‐dose VKA (moderate certainty).
1 finding from 1 review
Cardiovascular mortality · adults with hypertension (patients with atrial fibrillation, congestive heart failure, pre‐eclampsia or pulmonary hypertension were…
Aspirin showed no clear difference in cardiovascular mortality compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
28‐day all‐cause mortality · hospitalised adults with COVID‐19 (moderate to severe disease)
The intervention probably leads to lower 28‐day all‐cause mortality (moderate certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality at day 45 · non‐hospitalised adults with mild COVID‐19
The intervention showed no clear difference in all‐cause mortality at day 45 (low certainty).
1 finding from 1 review